The Medical Letter on Drugs and Therapeutics
Ibalizumab-uiyk (Trogarzo) for Multidrug-Resistant HIV
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ibalizumab-uiyk (Trogarzo – Theratechnologies/TaiMed), a CD4-directed monoclonal antibody, for IV treatment of multidrug-resistant HIV-1 (MDR-HIV) infection in heavily antiretroviral-experienced adults with treatment failure on their current regimen. Ibalizumab-uiyk is the first biologic drug to be approved by the FDA for treatment of HIV-1 infection.

MDR-HIV INFECTION — When full virologic suppression (viral load <50 copies/mL) cannot be achieved in patients with HIV-1 infection because of resistance to all available therapeutic options, goals of treatment should include preventing clinical progression and mitigating further development of resistance that might compromise future treatment options. Partial virologic suppression has been associated with clinical benefit1,2; even when viremia occurs and the CD4+ count does not ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ibalizumab-uiyk (Trogarzo) for Multidrug-Resistant HIV
Article code: 1545b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian